Cannabidiol (CBD), one of the cannabinoids having non-psychotropic activity and derived from Cannabis sativa, has evoked great scientific curiosity on account of its wide-ranging applications. This compound has displayed its effectiveness as an anti-seizure, neuroprotective, antipsychotic, antidepressant, and anxiolytic agent. The neuroprotective action of CBD is related to its excellent antioxidant and anti-inflammatory nature. The outcome of scientific studies collected so far has shown promise in the application of CBD in clinical treatments for patients who are resistant to conventional anti-epileptic medications.
This study examines the efficacy of Cannabidiol in reducing seizures resulting from CNS infection with Theiler’s murine encephalomyelitis virus. In the said research mice were infected with Theiler’s murine encephalomyelitis virus (TMEV) acquired behavioral seizures during the first week of infection and later developed chronic epilepsy. The TMEV model presents an effective platform to examine novel antiseizure therapeutics. This study was undertaken to assess the efficiency of cannabidiol (CBD) in minimizing acute seizures resulting from viral infection.
Results Of The Research
Cannabidiol in the dosage 180mg/kg; 360 mg/kg/day reduced both the frequency and intensity of acute behavioral seizures following TMEV infection. It was also found that 150 mg/kg of CBD did not produce an overall improvement in seizure outcome. The time to peak effect (TPE) of CBD in the 6 Hz 32 mA psychomotor seizure examination using C57BL/6J mice was monitored at 2 hours following CBD treatment. What was noteworthy is that CBD (150 mg/kg) significantly decreased the frequency and severity of TMEV-induced acute seizures at 2 hours following CBD treatment. These results indicated that CBD has the potential to decrease TMEV-induced acute seizures when the seizure test is carried out at the TPE of CBD.
Relevance Of The Study
Cannabinoids is continuously researched and studied for their potential antiseizure effects. Numerous preclinical and clinical studies have proved that CBD can be considered a potent therapy for intractable epilepsies. The present study supports those previous findings and offers scope to examine pharmacokinetics, pharmacodynamics, and mechanisms of antiseizure effects of CBD within the TMEV model, which can aid to build future clinical research in an effective way.
Study: Main Features
- High dose (180 mg/kg) of CBD is effective in decreasing acute behavioral seizures caused by TMEV infection in C57BL/6J mice.
- The duration taken by CBD to peak effect is 2 hours post-treatment C57BL/6J mice on the basis of the 6 Hz 32mA psychomotor seizure test.
- Lower does of CBD (150 mg/kg) does not impact overall TMEV caused acute seizures’, but lessens the frequency and severity of seizures when assessed at 2 hours following CBD treatment.
- The TMEV model of infection-induced epilepsy is a beneficial tool to assess the efficacy of new anti-seizure treatments.
Epilepsy continues to be a serious neurological ailment despite the availability of numerous antiseizure drugs (ASDs), as almost 30% of epilepsy patients are pharmacoresistant to therapy. This medical concern requires exploring novel therapies to regulate seizures. Cannabidiol (CBD), a nonpsychogenic constituent of the Cannabis sativa plant, has drawn clinical attention for treating refractory epilepsies. The results from the randomized double-blinded placebo-controlled clinical trials of CBD disclosed substantial reduction in convulsive seizure frequency in patients with two rare and acute type of epilepsy – Dravet syndrome and Lennox-Gastaut syndrome. Based on such outcome, the US Food and Drug Administration recently acclaimed Epidiolex (highly purified CBD oral solution) for treating seizures linked with both of these syndromes. These findings call for further studies to verify the effectiveness of CBD in different types of hereditary and acquired epilepsies.